Active surveillance of prostate cancer leads to improved quality of life
the ONA take:
Prostate cancer is usually a slow-growing cancer. As a result, many men can opt to delay or avoid undergoing treatment. The process, referred to as active surveillance, allows men with prostate cancer to delay or avoid the side effects of its treatment as well.
Although the side effects of prostate cancer treatment can affect quality of life, the impact active surveillance has on quality of life is questionable. In this study, researchers found 10 previous studies that examined quality of life and other psychological issues related to men coping with prostate cancer.
The studies included 966 men with prostate cancer, all of whom chose active surveillance over aggressive treatment.
The results of this review show that quality of life scores for men who chose active surveillance were similar to the scores for men who chose surgery. Anxiety, depression, and general distress scores also were not worse in the active surveillance group.
The researchers conclude that although men who opt for active surveillance do not experience worse quality of life, they should still be assessed for potential problems and offered support as needed.
Active surveillance allows men with prostate cancer to delay or avoid the side effects of its treatment as well.
Additionally, the men who decided to track their cancers in a process known as "active surveillance" did not appear to suffer added emotional stress, researchers found. "The men in our study did not appear to suffer from any major negative psychological impacts, including anxiety and depression," said Dr. Lara Bellardita, the study's lead author from the IRCCS Foundation's National Cancer Institute in Milan, Italy.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|